Phase 1 Immune Deficiency Clinical Trials

3 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–3 of 3 trials

Recruiting

Phase 1Phase 2

Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)

Viral InfectionPrimary Immune Deficiency Disorder

New York Medical College40 enrolled7 locationsNCT04197596

Recruiting

Phase 1Phase 2

Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector

Adenosine Deaminase Severe Combined Immune Deficiency

University of California, Los Angeles20 enrolled1 locationNCT05432310

Active

Phase 1

Study to evaluate the safety and immunogenicity of an HIV-1 vaccine regimen of adjuvanted UVAX-1107 followed by adjuvanted UVAX-1107 or adjuvanted UVAX-1197 in healthy subjects aged 25-55 years.

Acquired immune deficiency syndrome (AIDS / HIV)

Uvax Bio Australia, Pty, Ltd, a wholly owned subsidiary of Uvax Bio, LLC34 enrolled1 locationACTRN12624000064505